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Introduction

Summary of Case Reports

§ Among 967 citations, 19 case reports involving 22
patients were identified and assessed in this study.
§ 45.5%, 31.8%, and 22.7% of the patients were taking
dabigatran, rivaroxaban, and apixaban, respectively.
§ 11 patients (50%) had mechanical valves, and 11
patients (50%) had bioprosthetic valves.
§ The average age of the patients was 65.2 years
(SD±14.3) with 54.5% female. 59.1% of the patients
had another indication for anticoagulation other than
heart valve replacement.
§ Of the patients with another indication for
anticoagulation, 92.3% had atrial fibrillation, and 7.7%
had deep vein thrombosis.
§ 13.6% of the cases reported concurrent aspirin use
§ 3 patients (13.6%) had cancer as a comorbid condition,
and 1 patient (4.5%) had a valve-in-valve replacement.
§ 95.5% of the 21 cases reported an intervention with 13
patients (61.9%) receiving surgery (11 valve
replacements, 2 thrombectomies) and 8 patients
(38.1%) receiving medical management.
§ 4.5% of the cases reported death prior to intervention.
§ The time reported from onset of DOAC therapy to
onset of thrombotic event ranged from 9 days to 33
months.

§ Direct oral anticoagulants (DOACs) are indicated to
treat and prevent venous thromboembolism and to
prevent stroke or systemic embolism in patients with
non-valvular atrial fibrillation.
§ The introduction of DOACs has provided an
alternative to warfarin for patients in need of oral
anticoagulation. It is, however, unclear whether
DOACs are safe and effective in patients with heart
valve replacement.
§ The RE-ALIGN trial published in 2013 did not
support the use of dabigatran in patients with
mechanical valve replacements; however, there are
ongoing studies, such as the PROACT Xa trial and
the ATLANTIS trial, investigating the use of other
DOACs in patients with heart valve replacements.
§ This purpose of this study is to evaluate and describe
a potential risk of thrombosis in patients with heart
valve replacement and treated with a DOAC.

Methods
§

§

Results

Following the PRISMA guidelines, a systematic
literature search was performed on June 24th, 2020
using three electronic databases (Pubmed, Embase,
Cochrane Library) with the following key terms:
(apixaban OR rivaroxaban OR edoxaban OR
dabigatran OR direct oral anticoagulant OR factor
Xa inhibitor OR direct thrombin inhibitor OR target
specific oral anticoagulant) and (valve replacement
OR valve implantation).
Two authors independently screened the search
result using Rayyan QCRI (a systematic review web
app). Different decisions were resolved through
consensus between the two authors with the input
of the third author.

Discussion
§ It is still uncertain whether DOACs are safe or effective
in preventing valve thrombosis for different types of
valve replacements.
§ The use of DOACs in patients with valve replacement
should be limited to those with no other alternative.
§ Further research is needed to determine the
effectiveness and safety of DOAC use in patients with
prior valve replacements.
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Disclosures
Table 1 – Characteristics of individual case reports
AF=Atrial Fibrillation; CABG=Coronary Artery Bypass Graft; RA=Rheumatoid Arthritis; CA=Cancer; CAD=Coronary Artery Disease; DVT=Deep Vein Thrombosis; IVDU=Intravenous Drug Use;
CHF=Congestive Heart Failure; MI=Myocardial Infarction; HTN=Hypertension; COPD=Chronic Obstructive Pulmonary Disease; TOF=Tetralogy of Fallot; HLD=Hyperlipidemia;
TAVR=Transcatheter Aortic Valve Replacement; TMVR=Transcatheter Mitral Valve Replacement; ASA=Aspirin; TPA=Tissue Plasminogen Activator; VSD=Ventricular Septal Defect; Tx=Treatment
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